share_log

Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25

Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25

貝爾德維持ORIC製藥的跑贏大盤,將目標股價下調至25美元
Moomoo 24/7 ·  03/12 08:06

Baird analyst Colleen Kusy maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Outperform and lowers the price target from $27 to $25.

貝爾德分析師科琳·庫西維持ORIC Pharmicals(納斯達克股票代碼:ORIC)的表現跑贏大盤,並將目標股價從27美元下調至25美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論